Related Experiment Videos
Tumor expression of Fas ligand (CD95L) and the consequences
P R Walker1, P Saas, P Y Dietrich
1Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 rue Micheli-du-Crest, CH-1211, Geneva 14, Switzerland. Paul.Walker@hcuge.ch
Abstract:
Tumors of diverse origin have recently been shown to express CD95 ligand and to induce apoptosis in CD95-expressing targets in vitro; however, in vivo, enhanced tumor growth and rejection have both been observed as a consequence of either immunosuppressive or proinflammatory functions of CD95 ligand. The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment.
Insights
Tumors express CD95 ligand, which can trigger cell death or promote tumor growth. The in vivo effect depends on the tumor microenvironment and complex immune interactions.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumors express CD95 ligand, a molecule known to induce apoptosis in target cells.
- The role of CD95 ligand in vivo is complex, with studies reporting both enhanced tumor growth and rejection.
- The ultimate impact of CD95 ligand on tumor progression is not fully understood.
Purpose of the Study:
- To investigate the dual role of CD95 ligand in tumor progression in vivo.
- To elucidate the mechanisms underlying the immunosuppressive and proinflammatory functions of CD95 ligand in the tumor microenvironment.
Main Methods:
- In vitro apoptosis assays using CD95-expressing target cells.
- In vivo studies analyzing tumor growth and rejection in different microenvironments.
- Analysis of immune cell populations and cytokine profiles associated with CD95 ligand expression.
Main Results:
- CD95 ligand expression by tumors can induce apoptosis in CD95-expressing targets in vitro.
- In vivo, CD95 ligand exhibited both tumor-promoting (immunosuppressive) and tumor-rejecting (proinflammatory) functions.
- The outcome of CD95 ligand expression in vivo is highly dependent on the specific tumor and its microenvironment.
Conclusions:
- CD95 ligand has context-dependent functions in cancer, acting as a double-edged sword.
- The balance between immunosuppressive and proinflammatory effects of CD95 ligand determines tumor fate.
- Targeting CD95 ligand in cancer therapy requires careful consideration of the tumor microenvironment.